Literature DB >> 361054

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 361054      PMCID: PMC483536          DOI: 10.1136/hrt.40.10.1069

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


× No keyword cloud information.
  30 in total

1.  RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY.

Authors:  W B KANNEL; T R DAWBER; G D FRIEDMAN; W E GLENNON; P M MCNAMARA
Journal:  Ann Intern Med       Date:  1964-11       Impact factor: 25.391

2.  Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate.

Authors:  J M THROP
Journal:  Lancet       Date:  1962-06-23       Impact factor: 79.321

3.  Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate.

Authors:  J M THORP; W S WARING
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

4.  The electrocardiogram in population studies. A classification system.

Authors:  H BLACKBURN; A KEYS; E SIMONSON; P RAUTAHARJU; S PUNSAR
Journal:  Circulation       Date:  1960-06       Impact factor: 29.690

5.  Bile acid kinetics and steroid balance during nicotinic acid therapy in patients with hyperlipoproteinemia types II and IV.

Authors:  K Einarsson; K Hellström; B Leijd
Journal:  J Lab Clin Med       Date:  1977-10

6.  Reduction of serum-lipid and uric-acid levels by an orally active androsterone.

Authors:  M F OLIVER
Journal:  Lancet       Date:  1962-06-23       Impact factor: 79.321

7.  Effect of clofibrate on glucose tolerance in maturity onset diabetes.

Authors:  D Barnett; J G Craig; D S Robinson; M P Rogers
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

8.  Effects of clofibrate on glucose tolerance, serum insulin, serum lipoproteins and plasma fibrinogen.

Authors:  H Lithell; J Boberg; H Hedstrand; K Hellsing; S Ljunghall; B Vessby
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

Review 9.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-02-02       Impact factor: 91.245

10.  The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.

Authors:  S C Enger; V Johnsen; A Samuelsen; E A Laws
Journal:  Acta Med Scand       Date:  1977
View more
  115 in total

1.  An ABC of drug-related problems.

Authors:  R H Meyboom; M Lindquist; A C Egberts
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

Review 2.  Fibrates for treatment of the metabolic syndrome.

Authors:  Kevin C Maki
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

3.  Frequency of citation and outcome of cholesterol lowering trials.

Authors:  P N Durrington; M F Laker; A Keech
Journal:  BMJ       Date:  1992-08-15

4.  The clofibrate saga: a retrospective commentary.

Authors:  Michael Oliver
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 5.  A comparative review of the adverse effects of treatments for hyperlipidaemia.

Authors:  A Steiner; B Weisser; W Vetter
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 6.  Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Authors:  K Mahdy Ali; A Wonnerth; K Huber; J Wojta
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

7.  Effect of clofibrate on brain mevalonate-5-pyrophosphate decarboxylase.

Authors:  M F Zafra; S Riquelme; M Castillo; E Garcia-Peregrin
Journal:  Neurochem Res       Date:  1987-09       Impact factor: 3.996

8.  Clinical and angiographic variables affecting the progression of coronary artery disease as determined by quantitative angiography.

Authors:  A Joseph; J D Talley; A Shih; T Crum; R Vogel; J Kupersmith
Journal:  Int J Card Imaging       Date:  1994-09

9.  The impact of therapeutic reference pricing on innovation in cardiovascular medicine.

Authors:  Desmond Sheridan; Jim Attridge
Journal:  Pharmacoeconomics       Date:  2006-12       Impact factor: 4.981

Review 10.  Statin therapy in the elderly: does it make good clinical and economic sense?

Authors:  Moira M B Mungall; Allan Gaw; James Shepherd
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.